Compare HALO & PPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HALO | PPC |
|---|---|---|
| Founded | 1998 | 1946 |
| Country | United States | United States |
| Employees | N/A | 52100 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Meat/Poultry/Fish |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.4B |
| IPO Year | 2001 | 1997 |
| Metric | HALO | PPC |
|---|---|---|
| Price | $69.32 | $33.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 3 |
| Target Price | ★ $78.18 | $41.33 |
| AVG Volume (30 Days) | ★ 1.2M | 870.4K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 6.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.56 | ★ 4.54 |
| Revenue | $151,862,000.00 | ★ $18,497,553,000.00 |
| Revenue This Year | $28.24 | $2.44 |
| Revenue Next Year | $12.56 | $1.83 |
| P/E Ratio | $26.03 | ★ $7.41 |
| Revenue Growth | N/A | ★ 3.46 |
| 52 Week Low | $47.50 | $32.79 |
| 52 Week High | $82.22 | $55.18 |
| Indicator | HALO | PPC |
|---|---|---|
| Relative Strength Index (RSI) | 59.68 | 32.17 |
| Support Level | $67.94 | N/A |
| Resistance Level | $71.53 | $38.86 |
| Average True Range (ATR) | 1.83 | 1.04 |
| MACD | 0.73 | -0.13 |
| Stochastic Oscillator | 96.73 | 21.05 |
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed JBS's offer undervalued Pilgrim's Pride.